Healthcare
Todos Medical Ltd.(TOMDF)
Live Price
Offline$0.00001
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- -37.1%
- EPS Growth
- +72.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Todos Medical Ltd. (TOMDF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -37.1%, EPS growth of +72.5%, a dividend yield of 0.0%. What stands out right now is revenue -37.1%, EPS +72.5%, free cash flow +77.4% with operating margin -126.7% and ROIC -243.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TOMDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-37.1% vs +7.6% peer median
Operating Margin
Below sector median
-126.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2022 was reported on Nov 15, 2022, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -37.1% and EPS is at +72.5%, with operating margin around -126.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2022 Nov 15, 2022 | โ | +0.0% | +0.0% | +0.0% |
2022 Jun 30, 2022 | โ | +0.0% | +0.0% | +0.0% |
2022 Mar 31, 2022 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TOMDF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TOMDF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TOMDF and SPY.
Company Overview
Todos Medical Ltd.
Other OTC
Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
- Leadership
- Gerald E. Commissiong
- IPO Date
- Aug 24, 2017
- Employees
- 7
- Street Address
- 121 Derech Menachem Begin
- Mailing
- Tel Aviv, 6701203
- Region
- Tel Aviv, IL
- Reporting Currency
- USD
- Investor Line
- 972 52 642 0126
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.0
- Price/Book
- โ
Growth
- Revenue
- -37.1%
- EPS
- +72.5%
- Free Cash Flow
- +77.4%
Profitability
- Gross Margin
- 56.0%
- Operating Margin
- -126.7%
- Net Margin
- -324.8%
- ROE
- 83.7%
- ROIC
- -243.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.20
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.